A clinician talks to a young patient who is lying in their hospital bed. There is a PrisMax machine in the background.

Expanding to Multi-Organ Support

Expand treatment possibilities for your patients by delivering single or combined multi-organ support therapies simultaneously on one device

Multi-organ dysfunction in critically ill patients

Multi-organ dysfunction is a life-threatening syndrome characterised by the dysfunction of two or more organ systems (neurologic, cardiovascular, renal, respiratory, haematologic, hepatic).1 Organ crosstalk, typically underpinned by systemic inflammatory and haemodynamic derangements, can potentiate the severity of multi-organ dysfunction.2-4

Nurse delivering multi-organ support at patient's bedside

Multi-organ dysfunction in the ICU

Multi-organ dysfunction is common in the ICU and can affect ~25-30% of critically ill patients.5,6

Deliver therapies simultaneously using a single vascular access

Management of multi-organ dysfunction is complex, requiring an integrated approach of pharmacologic and organ support therapies to both support individual organs and manage the effects of organ crosstalk.7 Clinicians can provide multi-organ support therapies using a single vascular access, helping to minimise the invasiveness of treatment8-10 and reduce the risk of infection for patients with multi-organ dysfunction.11-13 Furthermore, 90% of healthcare professionals have said that using a single system for multi-organ dysfunction would drive efficiencies for their hospital system.14

Benefits of single-system multi-organ support

Using a single device helps reduce complexity in an already complex environment.15,16

Expand

The integrated Vantive acute therapies portfolio expands treatment possibilities for patients with multi-organ dysfunction, helping clinicians to provide quality care. 

Personalise

Simultaneous delivery of CRRT and other organ support therapies is possible with the PrisMax system, enabling personalised treatment through a single vascular access.17,18

Healthcare professional sitting at table on laptop

Your educational partner as in expanding treatment possibilities

Access learning resources through the Vantive Learning Services  on-demand learning hub for support as in increasing therapy options in the ICU. This on-demand learning hub includes curated resources that enable clinicians to handle challenging situations with certainty and confidence.

Vantive Learning Services on-demand learning hub

Related products

Vantive, Oxiris, PrisMax and PrismaLung+ are trademarks of Vantive Health LLC or its affiliates. 

References

  1. Marshall JC. The multiple organ dysfunction syndrome. In Surgical Treatment: Evidence-Based and Problem Orientated. 2001. Accessed November 2021. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6868/.

  2. Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31(7):1380-1383.

  3. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8:738-742.

  4. Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney cross-talk in the critically ill patient. Am J Respir Crit Care Med. 2016;194(4):402-414.

  5. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-353.

  6. Vincent JL, Lefrant JY, Kotfis K, et al. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Int Care Med. 2018;44(3):337-344.

  7. Ronco C, Ricci Z, Husain-Syed F. From multiple organ support therapy to extracorporeal organ support in critically ill patients. Blood Purif. 2019;48(2):99-105.

  8. Consales G, Zamidei L, Turani F, et al. Combined renal-pulmonary extracorporeal support with low blood flow techniques: a retrospective observational study (CICERO Study). Blood Purif. 2022;51(4):299-308.

  9. Allardet-Servent J, Castanier M, Seignouret T, et al. Safety and efficacy of combined extracorporeal CO2 removal and renal replacement therapy in patients with acute respiratory distress syndrome and acute kidney injury: the pulmonary and renal support in acute respiratory distress syndrome study. Crit Care Med. 2015;43(12):2570-2581.

  10. Nentwich J, Wichmann D, Kluge S, Lindau S, Mutlak H, John S. Low-flow CO2 removal in combination with renal replacement therapy effectively reduces ventilation requirements in hypercapnic patients: a pilot study. Ann Intensive Care. 2019;9(1):3.

  11. Joint Commission. Central line-associated bloodstream infections toolkit and monograph. Available at: https://www.jointcommission.org/-/media/tjc/documents/resources/hai/clabsi_monographpdf.pdf (accessed November 2021).

  12. Dube WC, Jacob JT, Zheng Z, et al. Comparison of rates of central line-associated bloodstream infections in patients with 1 vs 2 central venous catheters. JAMA Netw Open. 2020;3(3):e200396.

  13. Concannon C, van Wijngaarden E, Stevens V, Dumyati G. The effect of multiple concurrent central venous catheters on central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2014;35(9):1140-1146.

  14. GLG Group. Prismaflex and Prismax Value Message Testing Market Research; 2021. 

  15. Takala J. Past and present challenges in ICU management. ICU Management. 2012;12(1):41-42.

  16. Pierce LNB. Patient safety and production pressure: ICU nursing perspective. APSF Newsletter. Spring 2001.

  17. PrisMax Operator’s Manual. March 2021.